首页> 外文期刊>Journal of the American College of Cardiology >GCH1 haplotype determines vascular and plasma biopterin availability in coronary artery disease effects on vascular superoxide production and endothelial function.
【24h】

GCH1 haplotype determines vascular and plasma biopterin availability in coronary artery disease effects on vascular superoxide production and endothelial function.

机译:GCH1单倍型决定了冠状动脉疾病中血管和血浆生物蝶呤的可用性对血管超氧化物产生和内皮功能的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVES: This study sought to determine the effects of endogenous tetrahydrobiopterin (BH4) bioavailability on endothelial nitric oxide synthase (eNOS) coupling, nitric oxide (NO) bioavailability, and vascular superoxide production in patients with coronary artery disease (CAD). BACKGROUND: GTP-cyclohydrolase I, encoded by the GCH1 gene, is the rate-limiting enzyme in the biosynthesis of BH4, an eNOS cofactor important for maintaining enzymatic coupling. We examined the associations between haplotypes of the GCH1 gene, GCH1 expression and biopterin levels, and the effects on endothelial function and vascular superoxide production. METHODS: Blood samples and segments of internal mammary arteries and saphenous veins were obtained from patients with CAD undergoing coronary artery bypass grafting (n = 347). The GCH1 haplotypes were defined by 3 polymorphisms: rs8007267GA, rs3783641AT, and rs10483639CG (X haplotype: A, T, G; O haplotype: any other combination). Vascular superoxide (+/- the eNOS inhibitor N(G)-nitro-L-arginine methyl ester [L-NAME]) was measured by lucigenin-enhanced chemiluminescence, whereas the vasorelaxations of saphenous veins to acetylcholine were evaluated ex vivo. RESULTS: Haplotype frequencies were OO 70.6%, XO 27.4%, and XX 2.0%. The X haplotype was associated with significantly lower vascular GCH1 messenger ribonucleic acid expression and substantial reductions in both plasma and vascular BH4 levels. In X haplotype carriers both vascular superoxide and L-NAME-inhibitable superoxide were significantly increased, and were associated with reduced vasorelaxations to acetylcholine. CONCLUSIONS: GCH1 gene expression, modulated by a particular GCH1 haplotype, is a major determinant of BH4 bioavailability both in plasma and in the vascular wall in patients with CAD. Genetic variation in GCH1 underlies important differences in endogenous BH4 availability and is a determinant of eNOS coupling, vascular redox state, and endothelial function in human vascular disease.
机译:目的:本研究旨在确定内源性四氢生物蝶呤(BH4)生物利用度对冠心病(CAD)患者内皮一氧化氮合酶(eNOS)偶联,一氧化氮(NO)生物利用度和血管超氧化物产生的影响。背景:由GCH1基因编码的GTP环水解酶I是生物合成BH4中的限速酶,BH4是对维持酶偶联重要的eNOS辅助因子。我们检查了GCH1基因的单倍型,GCH1表达和生物蝶呤水平之间的关联,以及对内皮功能和血管超氧化物产生的影响。方法:从接受冠状动脉搭桥术的冠心病患者(n = 347)中获取血样以及内乳动脉和隐静脉段。 GCH1单倍型由3个多态性定义:rs8007267G

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号